Table 1.
Summary of the composition of the different developed formulations.
| Formulations | Polymers | Lipids | TAAa | TLRb ligands | GalCerc |
|---|---|---|---|---|---|
| M+G+GalCer control mixture | – | – | Melan-A:26d gp100:44e | CpGh & MPLAi | Yes |
| NP[Md] | 90% (w/w) PLGA + 10% (w/w) PLGA-PEG | POPCf/DMPGg | Melan-A:26d | No | |
| NP[M+Ge] | Melan-A:26d gp100:44e |
No | |||
| NP[M+G+GalCer ] | Melan-A:26d gp100:44e |
Yes |
a
Tumor-associated antigens.
b
Toll-like receptor.
c
α-Galactosylceramide.
d
Melan-A (26–35(27L), sequence ELAGIGILTV).
e
gp100 (44–59), sequence WNRQLYPEWTEAQRLD.
f
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine.
g
1,2-Pimyristoyl-sn-glycero-3-phospho-rac-glycerol.
h
Synthetic unmethylated CpG oligodeoxynucleotides (CpG ODN).
i
Monophosphoryl lipid A.